Advertisement

Regulatory and Economic Aspects in Oncology

  • Evelyn Walter

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 213)

Table of contents

  1. Front Matter
    Pages i-vii
  2. Evelyn Walter
    Pages 1-5
  3. Clement Francois, Junwen Zhou, Michał Pochopien, Leila Achour, Mondher Toumi
    Pages 25-38
  4. Szymon Jarosławski, Eve Hanna, Monique Dabbous, Lylia Chachoua, Mondher Toumi
    Pages 39-55
  5. Mondher Toumi, Szymon Jarosławski, Christos Chouhaid, Bruno Fallissard, P. Auquier
    Pages 57-65
  6. Evelyn Walter
    Pages 85-108
  7. Daria Korchagina, Szymon Jaroslawski, Guy Jadot, Mondher Toumi
    Pages 109-142
  8. William Green, Matthew Taylor
    Pages 143-151
  9. Patricia M. Danzon
    Pages 153-167
  10. Nikolaus Knoepffler, Jürgen Zerth, Martin O’Malley
    Pages 189-205

About this book

Introduction

This book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society’s willingness to pay.

Keywords

Cancer Targeted Therapy Monoclonal antibodies Personalized Cancer Therapy Immunotherapy Health Economics Cost-effectiveness Analysis Cost-utility Analysis Health Technology Assessments Pricing Quality-Adjusted-Life-Year Willingness to Pay Willingness to Pay

Editors and affiliations

  • Evelyn Walter
    • 1
  1. 1.Institute for Pharmaeconomic ResearchViennaAustria

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-030-01207-6
  • Copyright Information Springer Nature Switzerland AG 2019
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-030-01206-9
  • Online ISBN 978-3-030-01207-6
  • Series Print ISSN 0080-0015
  • Series Online ISSN 2197-6767
  • Buy this book on publisher's site